P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA

Ngā tūemi rite

• Current status and research directions in acute myeloid leukemia
  mā: Hagop Kantarjian, me ētahi atu.
  I whakaputaina: (2024-09-01)
• P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA
  mā: Aram Bidikian, me ētahi atu.
  I whakaputaina: (2023-08-01)
• Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia
  mā: Roberta S. Azevedo, me ētahi atu.
  I whakaputaina: (2025-06-01)
• P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
  mā: Daniel Nguyen, me ētahi atu.
  I whakaputaina: (2023-08-01)
• Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin
  mā: Jayastu Senapati, me ētahi atu.
  I whakaputaina: (2024-08-01)